NCT00675428View on ClinicalTrials.gov

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

BG00002 (natalizumab)

Trial Locations (2)

Unknown

Research Center, Scottsdale

Research Center, Rochester

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00675428 - Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter